MannKind Corporation - Common Stock — 현금 흐름 (NASDAQ:MNKD)

Financials

영업활동으로 인한 현금 -28.13 M-61.71 M-80.68 M34.09 M42.51 M18.25 M 19.27 M 투자 활동으로 인한 현금 15.22 M-151.54 M4.87 M-1.99 M-96.65 M-304.8 M -292.04 M 재무활동으로 인한 현금 49.85 M270.27 M21.39 M136.61 M-137.27 M315.1 M 278.3 M 잉여 현금 흐름 -28.13 M-61.71 M-80.68 M34.09 M42.51 M13.69 M 13.15 M

MannKind Corporation - Common Stock

MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991. MannKind Corporation was named after its founder, Alfred E. Mann.

MNKD

Financials

MannKind Corporation - Common Stock

뉴스

MannKind Corporation (MNKD) Discusses FDA Approval of Afrezza for Pediatric Diabetes Patients Ages 6 and Older Transcript

Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics

MannKind (MNKD) Reports Q1 Loss, Misses Revenue Estimates

Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates

MannKind: Strategic Uncertainty Follows United Therapeutics’ Pivot (NASDAQ:MNKD)

맨카인드, Barclays 헬스케어 컨퍼런스 참가: 전략적 성장과 혁신

MannKind at Barclays Healthcare Conference: Strategic Growth and Innovation

MannKind Corporation (MNKD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

맨카인드, Leerink 헬스케어 컨퍼런스 참가: 제약 분야 확장 모색

MannKind at Leerink Global Healthcare: Expanding Horizons in Pharma

맨카인드, 당뇨병 학회서 Afrezza 데이터 발표

MannKind presents Afrezza data at diabetes conference